Charnwood Molecular, a leading UK-based pre-clinical discovery CRO serving the global pharmaceutical and biotechnology market, has added a range of new solid-state capabilities to its portfolio through a new collaborative partnership with Barcelona-based Solitek.
The sector-leading expertise and technology development within Solitek combines an excellent understanding of the diversity of the solid form landscape exhibited by small APIs with the experience and the practical know-how required to add value to new chemical entities. This parallel offering will augment Charnwood’s own provision of integrated drug discovery services.
Solitek clients will now benefit from access to Charnwood’s world-class discovery and development offering which, after Charnwood’s recent acquisition of Aurelia Bioscience, now combines biological assay development. Recent venture capital investment has ensured that our flagship services in computational and medicinal chemistry, and process research & development are world-class.
CEO of Charnwood Molecular, Steve Allin, commented: “We are very pleased to be able to offer our clients access to the expertise and capabilities provided by Solitek in solid state development, including characterization, solid form screening and selection, and crystallization process development. At Charnwood Molecular, we are driven to become the provider of choice for integrated drug discovery and development services within the global life sciences sector and to reducing the time and related cost implications from early stage discoveries and the clinic. At the beginning of the candidate development lifecycle, we encourage our clients to consider and confront the challenges awaiting them in the development phase in their drug discovery journey, and an enhanced understanding of the physicochemical properties of a molecule, provided through our collaboration with Solitek, is a key part of that challenge.”
Solitek Operations Director and co-founder, Victor Diaz, added “Charnwood Molecular has a very dynamic and enthusiastic team and are growing at a significant pace. We believe that Charnwood Molecular and Solitek’s services are complementary and are certain that this partnership will bring growth to both companies, and more importantly, to our clients. In addition to providing crystallization expertise in later stages of development, Solitek is focusing on adding value to late discovery or preclinical development programmes, so our clients can bring their candidate drugs forward into clinical development with a greater chance of success. Our collaboration with Charnwood Molecular allows us to work directly and seamlessly with their clients and provide them with the appropriate tools to know what challenges they are likely to face in later development stages, allowing them to plan in advance and to make informed decisions as to what candidates to progress.”